A carregar...
CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1(T315I)+ clones in TKI-resistant CML
PURPOSE: Ponatinib is the only approved tyrosine kinase inhibitor (TKI) suppressing BCR-ABL1(T315I)-mutated cells in chronic myeloid leukemia (CML). However, due to side effects and resistance, BCR-ABL1(T315I)-mutated CML remains a clinical challenge. Hydroxyurea (HU) has been used for cytoreduction...
Na minha lista:
| Publicado no: | EBioMedicine |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elsevier
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6921367/ https://ncbi.nlm.nih.gov/pubmed/31761618 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2019.11.004 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|